Detalhe da pesquisa
1.
Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data.
Int J Obes (Lond)
; 45(5): 923-933, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33462358
2.
PATIENTS ACHIEVING GOOD GLYCEMIC CONTROL (HBA1c <7%) EXPERIENCE A LOWER RATE OF HYPOGLYCEMIA WITH INSULIN DEGLUDEC THAN WITH INSULIN GLARGINE: A META-ANALYSIS OF PHASE 3A TRIALS.
Endocr Pract
; 21(8): 917-26, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26121451
3.
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Lancet
; 379(9825): 1498-507, 2012 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-22521072
4.
Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity.
Mol Metab
; 78: 101801, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37690519
5.
Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.
Lancet
; 377(9769): 924-31, 2011 Mar 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-21396703
6.
Effects of Dietary Self-Monitoring, Physical Activity, Liraglutide 3.0 mg, and Placebo on Weight Loss in the SCALE IBT Trial.
Obes Facts
; 13(6): 572-583, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33197917
7.
Developing, Planning and Conducting an Interim Analysis: Lessons From the DEVOTE Cardiovascular Outcomes Trial (Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events).
Ther Innov Regul Sci
; 53(2): 279-286, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29793353
8.
Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial.
Pediatr Diabetes
; 9(6): 554-60, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-18761644
9.
Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials.
J Diabetes Complications
; 31(7): 1164-1168, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28462892
10.
A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.
Diabetes Care
; 28(5): 1107-12, 2005 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-15855574
11.
Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.
Diabetes
; 53(6): 1614-20, 2004 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15161770
12.
[Will publication of quality indicators in the health service improve the quality? International experiences and Danish perspectives]. / Fører offentliggørelse af kvalitetsmålinger i sundhedsvaesenet til bedre kvalitet? Internationale erfaringer og danske perspektiver.
Ugeskr Laeger
; 164(38): 4380-4, 2002 Sep 16.
Artigo
em Dinamarquês
| MEDLINE | ID: mdl-12362726
13.
Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long).
Diabetes Care
; 35(12): 2464-71, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23043166
14.
Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial.
Eur J Endocrinol
; 167(2): 287-94, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22660026
15.
Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.
Diabetes Care
; 34(3): 661-5, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21270174
16.
[Ranking lists over hospital quality--do they serve as a guidance or are they misleading? On methodological problems in connection with announcement of quality indicators]. / Ranglister over sygehuses kvalitet--er de vejledende eller er de vildledende? Om metodiske problemer ved offentliggørelse af kvalitetsindikatorer.
Ugeskr Laeger
; 164(38): 4385-8, 2002 Sep 16.
Artigo
em Dinamarquês
| MEDLINE | ID: mdl-12362727